Protocol Ledger

NCT06111638 · Phase II/III · RECRUITING

Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs

Interventional Phase II/III clinical trial protocol NCT06111638 sponsored by Shanghai Xinzhi BioMed Co in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-01-03 Enrollment: 55 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06111638
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)55 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06111638
Protocol FieldVerified Registry Value
NCT IdentifierNCT06111638
Consolidated Lead SponsorShanghai Xinzhi BioMed Co
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment55 participants (ESTIMATED)
Registered Start Date2024-01-03
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI